Review

Public Health

Modern Biomedical Technologies versus Emerging Pathogenic Microbes

Insights into the Confronting Situation

Lalit Umesh, Sanish Verma*

Delhi University, Benito Juarez Marg, South Campus, South Moti Bagh, New Delhi, Delhi 110021, India
*: All correspondence should be sent to: Dr. Sanish Verma
Authors' Contact: Lalit Umesh, M.A., E-mail: lalit_umesh@outlook.com; Dr. Sanish Verma, Ph.D., M.Sc., E-mail: sanish.verma@gmail.com
DOI: https://doi.org/10.15354/si.24.re1042
Funding: No funding source declared.
COI: The authors declare no competing interest.
AI Declaration: The authors affirm that artificial intelligence did not contribute to the process of preparing the work.

The interaction between modern biomedical technologies and newly identified pathogenic microbes has become a crucial focus in the field of healthcare and illness management. The ongoing progress in technology is transforming the field of medical science. However, the advent of new and changing microbial dangers presents obstacles that require creative solutions. This article explores the delicate equilibrium between the capabilities of advanced biomedical technologies and the continuous development of disease-causing microorganisms. It provides new insights that influence the ongoing struggle between scientific advancement and the problems posed by these microbes.

Keywords: Emerging Pathogens; Fatality; Biomedical Technology; Human Crisis; Strategies

Science Insights, 2024 August 31; Vol. 45, No. 2, pp.1475-1481.

Introduction

IT IS CHALLENGING to anticipate the eventual victorious party in the ongoing conflict between biomedical technologies and new pathogenic microorganisms. The struggle is dynamic and complex, as both are continuously adapting and evolving in response to one another. In recent years, biomedical technologies have made significant progress, allowing healthcare professionals and researchers to diagnose, treat, and prevent a diverse array of diseases (1, 2). These technologies have transformed the healthcare industry and enhanced patient outcomes, ranging from advanced imaging techniques to personalized medicine (3). Nevertheless, pathogenic microorganisms appear to devise a method to circumvent new technologies as soon as they are introduced.

However, global public health is still at risk due to the emergence of new pathogenic organisms (4). These organisms present a substantial challenge to the healthcare system and society as a whole as the recent COVID-19 pandemic is an exact example. Although it may appear to be an endless conflict, it is crucial to recognize that both parties possess their own strengths and vulnerabilities. Innovation and cutting-edge research are the advantages of biomedical technologies, whereas adaptability and resilience are the advantages of emerging pathogenic microbes (5). Finding a balance between the two and utilizing the strengths of each party to outsmart the other is the key to winning this battle.

Understanding Emerging Pathogenic Microbes

The field of public health is increasingly concerned with the emergence of pathogenic microbes, as they continue to present new challenges for healthcare providers and scientists. These microbes are frequently novel or previously unidentified pathogens that have the capacity to induce infectious diseases in humans, animals, and plants. It is crucial to comprehend these emerging pathogens in order to create effective prevention and treatment strategies that will reduce their impact on global health.

The capacity of emerging pathogenic microbes to swiftly evolve and adapt to changing environmental conditions is one of the reasons they pose a significant threat (6). This may enable them to infect new hosts, develop resistance to antimicrobial drugs, or become more virulent. For instance, the emergence of multidrug-resistant bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA), has resulted in increased mortality rates and more challenging-to-treat infections in hospitals and communities (7).

The dissemination of emerging pathogens has also been influenced by globalization, as well as increased travel and trade. Infectious diseases are also accelerated by the rapid movement of people and products around the world (8). This can result in the rapid dissemination of new pathogens across borders, which can make it challenging to contain outbreaks and regulate transmission. The recent COVID-19 pandemic serves as a stark reminder of the interconnectedness of the world and the rapid global dissemination of a novel virus (9).

The emergence of novel pathogens is also influenced by climate change. The expansion of vector-borne diseases, including Zika virus, Dengue fever, and Lyme disease, can be facilitated by changes in rainfall patterns, altered ecosystems, and rising temperatures (10, 11). These environmental changes can also affect the distribution of wildlife reservoirs and increase the probability of zoonotic spillover events, which occur when pathogens transfer from animals to humans.

We are able to more accurately and rapidly identify and characterize emerging pathogens as a result of technological advancements in genomic sequencing and diagnostic tools. This has facilitated a more comprehensive comprehension of their genetic composition, transmission dynamics, and potential treatment options. The rapid sequencing of the virus's genome and the dissemination of data among scientists worldwide enabled the development of mRNA vaccines for COVID-19 in record time (12, 13).

The Threat of Emerging Pathogenic Microbes: Challenges and Implications

Rise of Pathogenic Microbes: Trends and Concerns

The growth of zoonotic diseases, which are infections that are transmitted from animals to humans, is one trend in the development of emerging pathogenic microbes. Animals have been implicated in the transmission of diseases such as Ebola, MERS, SARS, SARS-CoV-19, and underscoring the necessity of enhanced surveillance and control measures in animal populations (14). It is critical to monitor and investigate potential reservoirs of zoonotic pathogens as the occurrence of spillover events increases due to the encroachment of humans on wildlife habitats.

The increase in antibiotic resistance among pathogenic microbes is another trend that is cause for concern. The development of resistant strains of bacteria has resulted from the overuse and misuse of antibiotics in both humans and animals, which has made it more challenging to treat infections. One of the most significant hazards to global health, as identified by the World Health Organization, is antibiotic resistance (15). This underscores the necessity of responsible antibiotic use and the development of alternative treatments.

The absence of effective surveillance and response systems in numerous regions of the globe is one of the obstacles to addressing emerging pathogens. The populations of developing countries are frequently exposed to the transmission of infectious diseases due to the absence of the necessary resources and infrastructure to detect and control outbreaks (16). The prevention and control of emerging pathogens on a global scale are contingent upon the investment in surveillance technology and the reinforcement of public health systems (17, 18).

The emergence of novel pathogens is also influenced by climate change, as the conditions for the transmission of infectious diseases can be facilitated by changes in precipitation patterns and rising temperatures. The need for adaptable public health strategies to address the impacts of climate change on infectious diseases is underscored by the fact that diseases such as malaria and dengue fever are already increasing in prevalence in areas that were previously unaffected (19, 20).

Increasing investment in the research and development of new remedies and vaccines is one potential solution to the threat of emerging pathogens. Technological innovations, including genome sequencing and bioinformatics, have transformed our comprehension of infectious diseases and introduced novel instruments for outbreak monitoring and management (21). By investing in research and development, we can develop effective strategies for prevention and treatment and remain ahead of emerging pathogens.

Global Health Implications of Emerging Microbial Threats

The world has experienced the emergence of numerous novel microbial threats in recent years, which have presented substantial challenges to global health. These threats encompass novel variants of bacteria, viruses, and other microorganisms that have the capacity to trigger catastrophic epidemics and pandemics (22). The global health implications of these emerging microbial threats are extensive, affecting not only the health and well-being of individuals but also the stability and security of nations and the global economy.

The potential for widespread outbreaks of infectious diseases is one of the main global health implications of emerging microbial threats. Ebola, Zika, and COVID-19 have demonstrated the rapid and effortless transmission of novel pathogens from one region to another, resulting in widespread illness and mortality (23). These outbreaks have underscored the necessity of robust public health systems and infrastructure to effectively contain and control the spread of infectious diseases, as well as the significance of global cooperation and coordination in re-

sponding to emerging microbial threats (24).

In addition to the acute health consequences of emerging microbial threats, there are also substantial economic repercussions. Disruptions in commerce and travel, as well as increased healthcare costs and lost productivity due to illness and death, can result from infectious disease outbreaks (25). The economic repercussions of this outbreak may have a cascading effect, affecting not only the countries directly afflicted but also those with close economic ties to them. The COVID-19 pandemic has resulted in a global economic recession, resulting in the loss of millions of jobs and the bankruptcy of businesses (26).

The potential for antimicrobial resistance to develop is another significant global health implication of emerging microbial threats. The emergence of drug-resistant strains of bacteria has been facilitated by the overuse and misuse of antibiotics and other antimicrobial agents (27). This has resulted in a more challenging treatment of infections and a rise in morbidity and mortality rates. A comprehensive approach that encompasses the development of new drugs and diagnostics, enhanced infection prevention and control measures, and better stewardship of antimicrobial agents is necessary to address this growing threat (28). Furthermore, emerging microbial hazards may have political and social repercussions. Stigma and discrimination against specific groups or populations can be exacerbated by fear and misinformation, which can impede efforts to control outbreaks and exacerbate social tensions (29). Furthermore, the response to infectious disease outbreaks can become politicized, as governments and leaders exploit the crisis to advance their own agendas or quell dissent (30). This can erode the trust in public health authorities and institutions, thereby complicating the communication of precise information and the implementation of effective control measures.

Therefore, a coordinated and multidisciplinary approach is necessary to address the global health implications of emerging microbial threats. This encompasses the enhancement of public health surveillance and response systems, the enhancement of access to healthcare and essential medications, the investment in research and development for new drugs and vaccines, and the promotion of international collaboration and cooperation. It is also necessary to address the underlying social, economic, and environmental factors that contribute to the emergence and spread of infectious diseases, such as poverty, urbanization, climate change, and land-use changes.

Harnessing Innovation: Strategies for Combating Pathogenic Microbes

Enhancing surveillance and monitoring systems is one of the most critical approaches to combating emerging pathogenic microbes. The development of effective containment and treatment strategies is contingent upon the early detection of new pathogens (31). We believe that healthcare providers can promptly identify new pathogens and implement the necessary measures to prevent their dissemination by establishing effective surveillance systems. This encompasses the surveillance of outbreaks, the analysis of transmission patterns, and the implementation of genetic sequencing to gain a more comprehensive understanding of the pathogens' evolution.

Investing in the research and development of new remedies and vaccines is another critical approach to combating emerging pathogens. It is pivotal to conduct ongoing research and the development of new therapies to combat these pathogens as they evolve and develop resistance to existing treatments. This encompasses the creation of novel diagnostic tools, vaccines, and antimicrobial medicines to more effectively prevent and treat emerging diseases (32, 33). By investing in research and development, we can ensure that we are always one step ahead of emerging pathogens and that public health is better protected.

Additionally, the promotion of international collaboration and information sharing is essential in the fight against emerging pathogens. The prevention of the spread of infectious diseases necessitates global cooperation, as diseases are not territorially bound (34). Countries can collaborate to create effective strategies for preventing pandemics and combating emerging pathogens by exchanging information, resources, and expertise (35, 36). This encompasses the exchange of data regarding outbreaks, the coordination of responses, and the collaboration on research and development initiatives.

Besides, it is crucial to enhance public health infrastructure in order to eradicate emerging pathogens. This encompasses the enhancement of sanitation and hygiene practices, the expansion of healthcare services, and the reinforcement of healthcare systems. Countries can more effectively address outbreaks, prevent the transmission of diseases, and safeguard vulnerable populations by establishing a robust public health infrastructure (37). It is important to invest in public health infrastructure to safeguard the health and well-being of communities worldwide and to combat emerging pathogens.

Education and public awareness are also critical strategies for the prevention of emerging pathogens. We can contribute to the prevention of the spread of pathogens and the reduction of the burden of emerging diseases by promoting healthy behaviors and educating the public about the risks of infectious diseases (38, 39). This encompasses the dissemination of precise information regarding infectious diseases, vaccination, and secure food practices, in addition to the promotion of handwashing. We can empower individuals to take action to safeguard themselves and their communities by increasing awareness of emerging pathogens.

Furthermore, the control of emerging pathogens necessitates the implementation of new technologies and innovations. The surveillance, diagnosis, and treatment of infectious diseases can be enhanced by technological advancements, including AI, genetic sequencing, and telemedicine (40, 41). By integrating new technologies into healthcare systems, we can enhance the delivery of healthcare, develop more effective treatments, and more effectively monitor and respond to emerging pathogens. In order to safeguard public health and combat emerging pathogens, innovation is essential.

Successes and Setbacks in the Battle between Technology and Microbes

Successful Application of Biomedical Technologies in Microbial Control

The COVID-19 pandemic has presented a distinctive challenge

to the global community, resulting in the infection of millions of individuals and the loss of innumerable lives (42). This crisis has necessitated the urgent development of innovative solutions to mitigate the virus's dissemination. The utilization of mRNA technology, which has been at the forefront of the COVID-19 response, is one such solution that has demonstrated significant potential.

mRNA technology, or messenger RNA technology, is a state-of-the-art approach to vaccine development that has been implemented in the development of COVID-19 vaccines (43, 44). This method entails the use of mRNA to direct cells in the body to produce a protein that initiates an immune response, thereby enabling the body to identify and combat the virus in the future. This technology has facilitated the rapid development of vaccines against COVID-19, resulting in the development of vaccines such as the Pfizer-BioNTech and Moderna vaccines in record time (45, 46).

The flexibility and rapidity of mRNA technology in vaccine development are among its most significant advantages. In contrast to conventional vaccines, which necessitate the use of live or inactivated viruses, mRNA vaccines can be developed by utilizing the virus's genetic sequence, thereby enabling a more efficient and expedited production process (47). The capacity to swiftly develop and deploy vaccines has been essential in the fight against COVID-19, as it has been instrumental in controlling the virus's spread and saving lives (48).

The safety profile of mRNA technology is another significant advantage. mRNA vaccines are safer to administer to patients, particularly those with compromised immune systems, because they do not contain any live virus (49, 50). Furthermore, the DNA of the recipient is not affected by mRNA vaccines, as the mRNA is rapidly degraded and does not integrate into the genome (51, 52). This renders mRNA vaccines a secure and efficient method of safeguarding against COVID-19.

The effectiveness of mRNA technology in the fight against the COVID-19 pandemic has been remarkable. Clinical trials have demonstrated that mRNA vaccines are highly effective in preventing COVID-19 infection, with efficacy rates exceeding 90% in certain instances (53). This has resulted in the implementation of extensive vaccination campaigns worldwide, which have served to mitigate the virus's global transmission and safeguard vulnerable populations from severe illness and mortality (54).

mRNA technology has the potential to revolutionize the development of vaccines for other infectious diseases in addition to its efficacy and safety. In response to emerging threats, such as future pandemics or outbreaks of other infectious diseases, mRNA vaccines are an appealing option due to their speed and efficacy. This has the capacity to avert future public health crises and save innumerable lives.

Challenges and Lessons Learned from Failed Strategies

The COVID-19 pandemic has presented a plethora of obstacles that have put the adaptability and resilience of governments, communities, and individuals to the test on a global scale. The rapid transmission of the virus and the difficulty in containing it have been two of the most significant challenges in the fight against COVID-19 (55). The virus's highly contagious nature and its capacity to propagate through asymptomatic carriers have rendered it exceedingly difficult to prevent its dissemination within communities. This has resulted in the implementation of rigorous confinement measures, social distancing guidelines, and mask mandates to mitigate the virus's transmission.

The strain on healthcare systems worldwide has been another significant obstacle in the fight against COVID-19. The abrupt influx of COVID-19 patients has resulted in a shortage of critical supplies, including personal protective equipment (PPE), ventilators, and hospital beds, which has overwhelmed hospitals and healthcare facilities. Despite the emotional toll of witnessing the devastation caused by the virus, healthcare professionals have been working tirelessly to care for patients, often at great personal risk (56-58). Increased investment in public health infrastructure and preparedness to more effectively address future health crises has been underscored by the pandemic.

The COVID-19 pandemic has also presented a substantial economic challenge for both individuals and enterprises. In particular, industries such as hospitality, tourism, and retail have experienced widespread employment losses and economic instability as a result of lockdown measures and restrictions on public gatherings (59). Many small businesses have been compelled to ultimately close due to the immense pressure they have encountered in order to remain afloat. Despite the fact that governments have implemented a variety of financial relief programs to assist individuals and businesses during this difficult period, the long-term economic repercussions of the pandemic remain uncertain.

Despite these obstacles, the war against COVID-19 has provided valuable insights that can be used to inform future responses to comparable health crises. Early and decisive action in response to a pandemic is a critical lesson. The virus was effectively controlled and its impact on public health was minimized by countries that promptly implemented rigorous containment measures, including widespread testing, contact tracing, and quarantine protocols.

The significance of international cooperation and collaboration in confronting global health threats is another critical lesson that has been acquired during the COVID-19 pandemic. The pandemic has underscored the necessity for coordinated international efforts to effectively combat infectious diseases and the interconnectedness of the globe. The development of vaccines, treatments, and public health strategies to combat the virus has been contingent upon collaborative research, data sharing, and resource allocation.

Conclusion

The field of healthcare has made significant strides in the detection, prevention, and treatment of diseases as a result of the rapid advancement of contemporary biomedical technologies. Nevertheless, the emergence of novel pathogenic microbes that have evolved to resist conventional treatments consistently impedes this progress. A complex interplay between evolving microbial threats and cutting-edge medical innovations is currently evident. AI, CRISPR-Cas9 gene editing, mRNA vaccines, and next-generation sequencing technologies are being employed to comprehend and combat these emerging pathogens. In order to

create targeted therapeutics, researchers are investigating their genetic composition, mechanisms of virulence, and potential vulnerabilities. In order to remain abreast of these microbial challenges and guarantee effective responses to future pandemics, it is imperative that we collaborate with scientists, clinicians, and policymakers as we traverse this constantly evolving landscape.■

References

1. Junaid SB, Imam AA, Balogun AO, De Silva LC, Surakat YA, Kumar G, Abdulkarim M, Shuaibu AN, Garba A, Sahalu Y, Mohammed A, Mohammed TY, Abdulkadir BA, Abba AA, Kakumi NAI, Mahamad S. Recent advancements in emerging technologies for healthcare management systems: A survey. Healthcare (Basel). 2022; 10(10):1940. DOI: https://doi.org/10.3390/healthcare10101940
2. Mahara G, Tian C, Xu X, Wang W. Revolutionising health care: Exploring the latest advances in medical sciences. J Glob Health 2023; 13:03042. DOI: https://doi.org/10.7189/jogh.13.03042
3. Bhatia R. Emerging health technologies and how they can transform healthcare delivery. J Health Manag 2021; 23(1):63-73. DOI: https://doi.org/10.1177/0972063421995025
4. Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, Takahashi S, Tatem AJ, Wagner CE, Wang LF, Wesolowski A, Metcalf CJE. Infectious disease in an era of global change. Nat Rev Microbiol 2022; 20(4):193-205. DOI: https://doi.org/10.1038/s41579-021-00639-z
5. Kamel M, Aleya S, Alsubih M, Aleya L. Microbiome dynamics: A paradigm shift in combatting infectious diseases. J Pers Med. 2024; 14(2):217. DOI: https://doi.org/10.3390/jpm14020217
6. Levitt AM, Khan AS, Hughes JM. Emerging and re-emerging pathogens and diseases. Infect Dis 2010; 2010:56-69. DOI: https://doi.org/10.1016/B978-0-323-04579-7.00004-6
7. Siddiqui AH, Koirala J. Methicillin-Resistant Staphylococcus aureus. [Updated 2023 Apr 2]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK482221/
8. Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, Takahashi S, Tatem AJ, Wagner CE, Wang LF, Wesolowski A, Metcalf CJE. Infectious disease in an era of global change. Nat Rev Microbiol 2022; 20(4):193-205. DOI: https://doi.org/10.1038/s41579-021-00639-z
9. Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie 2020; 179:85-100. DOI: https://doi.org/10.1016/j.biochi.2020.09.018
10. Caminade C, McIntyre KM, Jones AE. Impact of recent and future climate change on vector-borne diseases. Ann N Y Acad Sci 2019; 1436(1):157-173. DOI: https://doi.org/10.1111/nyas.13950
11. Mojahed N, Mohammadkhani MA, Mohamadkhani A. Climate crises and developing vector-borne diseases: A narrative review. Iran J Public Health 2022; 51(12):2664-2673. DOI: https://doi.org/10.18502/ijph.v51i12.11457
12. Demongeot J, Fougère C. mRNA COVID-19 vaccines-facts and hypotheses on fragmentation and encapsulation. Vaccines (Basel) 2022; 11(1):40. DOI: https://doi.org/10.3390/vaccines11010040
13. Barrett ADT, Titball RW, MacAry PA, Rupp RE, von Messling V, Walker DH, Fanget NVJ. The rapid progress in COVID vaccine development and implementation. NPJ Vaccines 2022; 7(1):20. DOI: https://doi.org/10.1038/s41541-022-00442-8
14. Fang R, Yang X, Guo Y, Peng B, Dong R, Li S, Xu S. SARS-CoV-2 infection in animals: Patterns, transmission routes, and drivers. Eco Environ Health 2023; 3(1):45-54. DOI: https://doi.org/10.1016/j.eehl.2023.09.004
15. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog Glob Health 2015; 109(7):309-318. DOI: https://doi.org/10.1179/2047773215Y.0000000030
16. Tosam MJ, Ambe JR, Chi PC. Global emerging pathogens, poverty and vulnerability: An ethical analysis. Socio-cult Dimen Emerg Infect Dis Afr 2019; 2019 :243-253. DOI: https://doi.org/10.1007/978-3-030-17474-3_18
17. Zhang XX, Jin YZ, Lu YH, Huang LL, Wu CX, Lv S, Chen Z, Xiang H, Zhou XN. Infectious disease control: from health security strengthening to health systems improvement at global level. Glob Health Res Policy 2023; 8(1):38. DOI: https://doi.org/10.1186/s41256-023-00319-w
18. + Cheng Y, Zhang Z, Shu Y, Ren L, Kang M, Kong D, Shi X, Lv Q, Chen Z, Li Y, Zhang R, Lu P, Lu Y, Liu T, Chen N, Xiong H, Du C, Yuan J, Wang L, Liu R, Chen W, Li X, Lin Q, Li G, Zhang X, Yuan J, Wang T, Guo Y, Lu J, Zou X, Feng T. Expert consensus on One Health for establishing an enhanced and integrated surveillance system for key infectious diseases. Infect Med (Beijing) 2024; 3(2):100106. DOI: https://doi.org/10.1016/j.imj.2024.100106
19. Piscitelli P, Miani A. Climate change and infectious diseases: Navigating the intersection through innovation and interdisciplinary approaches. Int J Environ Res Public Health 2024; 21(3):314. DOI:

https://doi.org/10.3390/ijerph21030314

20. Grobusch LC, Grobusch MP. A hot topic at the environment-health nexus: investigating the impact of climate change on infectious diseases. Int J Infect Dis 2022; 116:7-9. DOI: https://doi.org/10.1016/j.ijid.2021.12.350
21. Bianconi I, Aschbacher R, Pagani E. Current uses and future perspectives of genomic technologies in clinical microbiology. Antibiotics (Basel) 2023; 12(11):1580. DOI: https://doi.org/10.3390/antibiotics12111580
22. Adalja AA, Watson M, Toner ES, Cicero A, Inglesby TV. Characteristics of microbes most likely to cause pandemics and global catastrophes. Curr Top Microbiol Immunol 2019; 424:1-20. DOI: https://doi.org/10.1007/82_2019_176
23. Khubchandani J, Jordan TR, Yang YT. Ebola, Zika, Corona…What is next for our world? Int J Environ Res Public Health 2020; 17(9):3171. DOI: https://doi.org/10.3390/ijerph17093171
24. Williams BA, Jones CH, Welch V, True JM. Outlook of pandemic preparedness in a post-COVID-19 world. NPJ Vaccines 2023; 8(1):178. DOI: https://doi.org/10.1038/s41541-023-00773-0
25. Samsudin EZ, Yasin SM, Ruslan NH, Abdullah NN, Noor AFA, Hair AFA. Socioeconomic impacts of airborne and droplet-borne infectious diseases on industries: A systematic review. BMC Infect Dis 2024; 24(1):93. DOI: https://doi.org/10.1186/s12879-024-08993-y
26. Naseer S, Khalid S, Parveen S, Abbass K, Song H, Achim MV. COVID-19 outbreak: Impact on global economy. Front Public Health 2023; 10:1009393. DOI: https://doi.org/10.3389/fpubh.2022.1009393
27. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: A narrative Review. Pharmaceuticals (Basel) 2023; 16(11):1615. DOI: https://doi.org/10.3390/ph16111615
28. Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial stewardship: Fighting antimicrobial resistance and protecting global public health. Infect Drug Resist 2020; 13:4713-4738. DOI: https://doi.org/10.2147/IDR.S290835
29. Saeed F, Mihan R, Mousavi SZ, Reniers RL, Bateni FS, Alikhani R, Mousavi SB. A narrative review of stigma related to infectious disease outbreaks: What can be learned in the face of the Covid-19 pandemic? Front Psychiatry 2020; 11:565919. DOI: https://doi.org/10.3389/fpsyt.2020.565919
30. Singer PM, Willison CE, Greer SL. Infectious disease, public health, and politics: United States response to Ebola and Zika. J Public Health Policy 2020; 41(4):399-409. DOI: https://doi.org/10.1057/s41271-020-00243-0
31. Madhav N, Oppenheim B, Gallivan M, et al. Pandemics: Risks, Impacts, and Mitigation. In: Jamison DT, Gelband H, Horton S, et al., editors. Disease Control Priorities: Improving Health and Reducing Poverty. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 27. Chapter 17. DOI: https://doi.org/10.1596/978-1-4648-0527-1_ch17
32. Clift C, Salisbury DM. Enhancing the role of vaccines in combatting antimicrobial resistance. Vaccine 2017; 35(48 Pt B):6591-6593. DOI: https://doi.org/10.1016/j.vaccine.2017.09.053
33. Micoli F, Bagnoli F, Rappuoli R, Serruto D. The role of vaccines in combatting antimicrobial resistance. Nat Rev Microbiol 2021 May; 19(5):287-302. DOI: https://doi.org/10.1038/s41579-020-00506-3
34. Institute of Medicine (US) Forum on Microbial Threats; Knobler S, Mahmoud A, Lemon S, et al., editors. The Impact of Globalization on Infectious Disease Emergence and Control: Exploring the Consequences and Opportunities: Workshop Summary. Washington (DC): National Academies Press (US); 2006. Summary and Assessment. Available at: https://www.ncbi.nlm.nih.gov/books/NBK56579/
35. Hameed M, Najafi M, Cheeti S, Sheokand A, Mago A, Desai S. Factors influencing international collaboration on the prevention of COVID-19. Public Health 2022; 212:95-101. DOI: https://doi.org/10.1016/j.puhe.2022.08.017
36. Kokudo N, Sugiyama H. Call for international cooperation and collaboration to effectively tackle the COVID-19 pandemic. Glob Health Med 2020; 2(2):60-62. DOI: https://doi.org/10.35772/ghm.2020.01019
37. Lal A, Abdalla SM, Chattu VK, Erondu NA, Lee TL, Singh S, Abou-Taleb H, Vega Morales J, Phelan A. Pandemic preparedness and response: Exploring the role of universal health coverage within the global health security architecture. Lancet Glob Health 2022; 10(11):e1675-e1683. DOI: https://doi.org/10.1016/S2214-109X(22)00341-2
38. Church DL. Major factors affecting the emergence and re-emergence of infectious diseases. Clin Lab Med 2004; 24(3):559-586, v. DOI: https://doi.org/10.1016/j.cll.2004.05.008
39. Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, Takahashi S, Tatem AJ, Wagner CE, Wang LF, Wesolowski A, Metcalf CJE. Infectious disease in an era of global change. Nat Rev Microbiol 2022; 20(4):193-205. DOI: https://doi.org/10.1038/s41579-021-00639-z
40. Abbo LM, Vasiliu-Feltes I. Disrupting the infectious disease ecosystem in the digital precision health era innovations and converging emerging technologies. Antimicrob Agents Chemother 2023; 67(10):e0075123. DOI: https://doi.org/10.1128/aac.00751-23
41. Abdallah S, Sharifa M, I Kh Almadhoun MK, Khawar MM Sr, Shaikh U, Balabel KM, Saleh I, Manzoor A, Mandal AK, Ekomwereren O, Khine WM, Oyelaja OT. The impact of artificial intelligence on optimizing diagnosis and treatment plans for rare genetic disorders. Cureus 2023; 15(10):e46860. DOI: https://doi.org/10.7759/cureus.46860
42. Sawicka B, Aslan I, Della Corte V, Periasamy A, Krishnamurthy SK, Mohammed A, Tolba Said MM, Saravanan P, Del Gaudio G, Adom D, Sawicki B, Nevola G, Hanchate DB, Umachandran K. The

coronavirus global pandemic and its impacts on society. Coronavirus Drug Discov 2022:267-311. DOI: https://doi.org/10.1016/B978-0-323-85156-5.00037-7

43. Ilyichev AA, Orlova LA, Sharabrin SV, Karpenko LI. mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development. Vavilovskii Zhurnal Genet Selektsii 2020; 24(7):802-807. DOI: https://doi.org/10.18699/VJ20.676
44. Al Fayez N, Nassar MS, Alshehri AA, Alnefaie MK, Almughem FA, Alshehri BY, Alawad AO, Tawfik EA. Recent advancement in mRNA vaccine development and applications. Pharmaceutics 2023; 15(7):1972. DOI: https://doi.org/10.3390/pharmaceutics15071972
45. Kuter BJ, Offit PA, Poland GA. The development of COVID-19 vaccines in the United States: Why and how so fast? Vaccine 2021; 39(18):2491-2495. DOI: https://doi.org/10.1016/j.vaccine.2021.03.077
46. Chakraborty C, Bhattacharya M, Dhama K. SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: The lessons learned might help to fight against the next pandemic. Vaccines (Basel) 2023; 11(3):682. DOI: https://doi.org/10.3390/vaccines11030682
47. Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine 2021; 39(16):2190-2200. DOI: https://doi.org/10.1016/j.vaccine.2021.03.038
48. Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, Khan W. A Comprehensive Review of mRNA Vaccines. Int J Mol Sci 2023; 24(3):2700. DOI: https://doi.org/10.3390/ijms24032700
49. Chavda VP, Jogi G, Dave S, Patel BM, Vineela Nalla L, Koradia K. mRNA-based vaccine for COVID-19: They are new but not unknown! Vaccines (Basel) 2023; 11(3):507. DOI: https://doi.org/10.3390/vaccines11030507
50. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. Nat Rev Drug Discov 2021; 20(11):817-838. DOI: https://doi.org/10.1038/s41573-021-00283-5. Erratum in: Nat Rev Drug Discov. 2021 Nov;20(11):880. DOI: https://doi.org/10.1038/s41573-021-00321-2
51. Koppu V, Poloju D, Puvvala B, Madineni K, Balaji S, Sheela CMP, Manchikanti SSC, Moon SM. Current perspectives and future prospects of mRNA vaccines against viral diseases: A brief review. Int J Mol Cell Med 2022; 11(3):260-272. DOI: https://doi.org/10.22088/IJMCM.BUMS.11.3.260
52. Acevedo-Whitehouse K, Bruno R. Potential health risks of mRNA-based vaccine therapy: A hypothesis. Med Hypotheses 2023; 171:111015. DOI: https://doi.org/10.1016/j.mehy.2023.111015
53. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384(5):403-416. DOI: https://doi.org/10.1056/NEJMoa2035389
54. Wu X, Xu K, Zhan P, Liu H, Zhang F, Song Y, Lv T. Comparative efficacy and safety of COVID-19 vaccines in phase III trials: A network meta-analysis. BMC Infect Dis 2024; 24(1):234. DOI: https://doi.org/10.1186/s12879-023-08754-3
55. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: A global health crisis. Physiol Genomics 2020; 52(11):549-557. DOI: https://doi.org/10.1152/physiolgenomics.00089.2020
56. Mehta S, Machado F, Kwizera A, Papazian L, Moss M, Azoulay É, Herridge M. COVID-19: A heavy toll on health-care workers. Lancet Respir Med 2021; 9(3):226-228. DOI: https://doi.org/10.1016/S2213-2600(21)00068-0
57. Mehedi N, Ismail Hossain M. Experiences of the frontline healthcare professionals amid the COVID-19 health hazard: A phenomenological investigation. Inquiry 2022; 59:469580221111925. DOI: https://doi.org/10.1177/00469580221111925
58. Søvold LE, Naslund JA, Kousoulis AA, Saxena S, Qoronfleh MW, Grobler C, Münter L. Prioritizing the mental health and well-being of healthcare workers: An urgent global public health priority. Front Public Health 2021; 9:679397. DOI: https://doi.org/10.3389/fpubh.2021.679397
59. Shapoval V, Hägglund P, Pizam A, Abraham V, Carlbäck M, Nygren T, Smith RM. The COVID-19 pandemic effects on the hospitality industry using social systems theory: A multi-country comparison. Int J Hosp Manag 2021; 94:102813. DOI: https://doi.org/10.1016/j.ijhm.2020.102813

Received: May 17, 2024 | Revised: June 24, 2024 | Accepted: June 28, 2024